IGC Pharma Inc (IGC)
0.3705
+0.01
(+2.35%)
USD |
NYAM |
Oct 04, 16:00
0.3622
-0.01
(-2.24%)
After-Hours: 20:00
IGC Pharma Research and Development Expense (TTM): 3.915M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 3.915M |
| March 31, 2024 | 3.773M |
| December 31, 2023 | 3.411M |
| September 30, 2023 | 3.314M |
| June 30, 2023 | 2.814M |
| March 31, 2023 | 3.461M |
| December 31, 2022 | 4.201M |
| September 30, 2022 | 3.772M |
| June 30, 2022 | 3.28M |
| March 31, 2022 | 2.33M |
| December 31, 2021 | 1.431M |
| September 30, 2021 | 1.208M |
| Date | Value |
|---|---|
| June 30, 2021 | 1.151M |
| March 31, 2021 | 0.929M |
| December 31, 2020 | 0.842M |
| September 30, 2020 | 0.983M |
| June 30, 2020 | 0.986M |
| March 31, 2020 | 1.011M |
| December 31, 2019 | 1.575M |
| September 30, 2019 | 1.446M |
| June 30, 2019 | 1.502M |
| March 31, 2019 | 1.291M |
| December 31, 2018 | 0.559M |
| September 30, 2018 | 0.393M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
0.842M
Minimum
Dec 2020
4.201M
Maximum
Dec 2022
2.336M
Average
2.33M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| CEL-SCI Corp | 18.95M |
| AIM ImmunoTech Inc | 9.03M |
| NovaBay Pharmaceuticals Inc | 0.043M |
| Protalix BioTherapeutics Inc | 12.62M |
| Palatin Technologies Inc | 22.40M |